We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+71.93%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$766M
AUM Growth
+$254M
Cap. Flow
+$25.8M
Cap. Flow %
3.37%
Top 10 Hldgs %
55.55%
Holding
68
New
13
Increased
17
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$7.81M
2
TCDA
Tricida, Inc. Common Stock
TCDA
+$7.36M
3
FSDC
FS Development Corp. Class A Common Stock
FSDC
+$7.27M
4
CYTK icon
Cytokinetics
CYTK
+$6.84M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$5.6M

Top Sells

Rank Stock Value
1
ATXI
Avenue Therapeutics, Inc. Common Stock
ATXI
+$10.7M
2
APTO
Aptose Biosciences, Inc.
APTO
+$5.22M
3
FULC icon
Fulcrum Therapeutics
FULC
+$4.11M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$3.76M
5
MGNX icon
MacroGenics
MGNX
+$3.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
26
MacroGenics
MGNX
$260M
$8.47M 1.11%
370,600
-156,400
-30% -$3.6M
FSDC
27
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$7.75M 1.01%
+704,400
New +$7.27M
PTGX icon
28
Protagonist Therapeutics
PTGX
$9.67B
$7.02M 0.92%
+260,000
New +$5.6M
STRO icon
29
Sutro Biopharma
STRO
$353M
$7M 0.91%
32,220
+17,620
+121% +$2.92M
AVTX icon
30
Avalo Therapeutics
AVTX
$1.08B
$6.92M 0.9%
910
-261
-22% -$1.81M
TCDA
31
DELISTED
Tricida, Inc. Common Stock
TCDA
$6.76M 0.88%
+959,000
New +$7.36M
INFI
32
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$6.72M 0.88%
3,171,800
– –
FPRX
33
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$6.5M 0.85%
+381,900
New +$4.78M
ADMS
34
DELISTED
Adamas Pharmaceuticals
ADMS
$6.44M 0.84%
1,487,800
– –
MRUS
35
DELISTED
Merus
MRUS
$6.19M 0.81%
353,000
+352,800
+176,400% +$5.21M
SIOX
36
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.56M 0.73%
2,000,000
-39,100
-2% -$114K
TELA icon
37
TELA Bio
TELA
$29.2M
$5.49M 0.72%
365,000
+2,926
+0.8% +$47.5K
KYNB
38
Kyntra Bio
KYNB
$32.4M
$5.45M 0.71%
5,880
– –
VSTM icon
39
Verastem
VSTM
$668M
$4.76M 0.62%
193,750
+10,417
+6% +$209K
LITS
40
Lite Strategy Inc
LITS
$34M
$4.11M 0.54%
77,800
– –
KNSA icon
41
Kiniksa Pharmaceuticals
KNSA
$6.23B
$3.96M 0.52%
224,100
-113,900
-34% -$2M
KZR
42
DELISTED
Kezar Life Sciences
KZR
$3.7M 0.48%
70,800
+3,000
+4% +$167K
APTO
43
DELISTED
Aptose Biosciences, Inc.
APTO
$3.5M 0.46%
1,778
-2,220
-56% -$5.22M
PRAX icon
44
Praxis Precision Medicines
PRAX
$10.3B
$3.49M 0.46%
+4,228
New +$2.47M
RYTM icon
45
Rhythm Pharmaceuticals
RYTM
$7.75B
$3.42M 0.45%
+115,000
New +$2.92M
FOCL
46
EDAP TMS S.A.
FOCL
$199M
$3.4M 0.44%
657,500
-382,500
-37% -$1.72M
EPIX
47
DELISTED
ESSA Pharma
EPIX
$3.39M 0.44%
284,050
+12,700
+5% +$89.4K
CNCE
48
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$3.21M 0.42%
254,000
+154,000
+154% +$1.76M
CFRX
49
DELISTED
ContraFect Corporation
CFRX
$2.22M 0.29%
5,500
+2,673
+95% +$1.16M
OPTN
50
DELISTED
OptiNose
OPTN
$1.8M 0.24%
+29,000
New +$1.78M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2020 Portfolio in Review

As of Q4 2020, Opaleye Management held 68 positions worth $766M, up 50% from $511M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opaleye Management deployed $25.8M of net new capital in Q4 2020, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was Tricida, Inc. Common Stock: 959,000 shares worth $6.76M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Aptose Biosciences, Inc., an estimated $5.22M trimmed.

  • Opaleye Management's largest Q4 2020 buy was Tricida, Inc. Common Stock: 959,000 shares worth $6.76M.
  • Opaleye Management added most to Ocular Therapeutix in Q4 2020, an estimated $7.81M increase.
  • Opaleye Management's biggest Q4 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $5.22M.
  • Opaleye Management fully exited Avenue Therapeutics, Inc. Common Stock in Q4 2020, selling an estimated $10.7M.
  • Opaleye Management's ten largest holdings make up 56% of its $766M portfolio in Q4 2020.
  • Opaleye Management opened 13 new positions and closed 9 in Q4 2020.
  • Opaleye Management's portfolio value rose 50% quarter-over-quarter to $766M.

Based on Opaleye Management's 13F filing for Q4 2020, filed 12 Feb 2021.